Autolus Therapeutics
AUTL
94 hedge funds and large institutions have $379M invested in Autolus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 20 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
45% more capital invested
Capital invested by funds: $261M → $379M (+$118M)
27% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 26
0.77% less ownership
Funds ownership: 63.16% → 62.39% (-0.77%)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
1% less funds holding
Funds holding: 95 → 94 (-1)
36% less call options, than puts
Call options by funds: $84K | Put options by funds: $131K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$28M |
| 2 |
AC
Armistice Capital
New York
|
+$1.65M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.56M |
| 4 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$1.49M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$15.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.05M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$4.95M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.23M |
| 5 |
Millennium Management
New York
|
-$3.08M |
AUTL Hedge Fund Activity: Q2 2025 in Review
94 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2025, worth a combined $379M — up 45% from $261M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AUTL and 19 opened new positions — a net loss of 1 holder — while 26 trimmed existing stakes and 33 added.
The largest buyer was MAK Capital One, opening a new position worth an estimated $28M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $15.4M sold.
- 94 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2025, down from 95 in Q1 2025.
- Funds reported $379M of Autolus Therapeutics stock for Q2 2025, up 45% quarter-over-quarter.
- 19 funds opened new Autolus Therapeutics positions in Q2 2025 and 20 closed out, a net change of -1 holder.
- The largest Autolus Therapeutics buyer in Q2 2025 was MAK Capital One, an estimated $28M added.
- The largest Autolus Therapeutics seller in Q2 2025 was Avoro Capital Advisors, an estimated $15.4M sold.
Based on aggregated 13F filings for Q2 2025.